Loading…

Verastem, Inc.VSTMCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 82
Mkt cap
$866M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$29.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · USD$6.87
1D-7.3%
1W-24.4%
1M-26.4%
3M+0.7%
6M+66.3%
YTD-11.0%
1Y-24.9%
ATR %9.6%
Beta1.06
52w lowhigh36.5% off high

What Verastem does

Employees: 102

Verastem at a glance

Size Verastem (VSTM) is a United States Health Care company (Biotechnology) with a market value of $866M, the 2316th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.87 on 18 Nov 2026.

Performance Over six months the shares gained 66.3%, against -16.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 649.6% over the last twelve months (peer median +2.5%); the operating margin is -193.7% (peer median -25.0%).

Valuation It trades at 8.2× enterprise value to sales against a peer median of 6.4× (8th most expensive of 19).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026VSTM 161Peer median 84
Six months, rebased to 100: Verastem against the median of its 20 peers (local-currency closes).

Verastem financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$100M$30.9M$10.0M$0$0
Revenue growth—+209%———
Gross profit$86.4M$25.6M$9.97M-$62,000-$118,000
EBITDA-$193M-$169M-$115M-$92.0M-$75.4M
Net income-$179M-$209M-$131M-$87.4M-$73.8M
Free cash flow-$160M-$138M-$105M-$86.5M-$63.7M
Capital expenditure$8.85M$9.62M$28,000$0$0
Total debt$129M$87.2M$42.3M$41.6M$27.1M

Quarterly statements and history in the cockpit →

Verastem competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%4587OXB2160300841ODTX688253MGTX688526GLUESNDX9887IVA688276SGPAURAINBX301333VSTM6-month return →1-month return →
Up and to the right = strong over both horizons. Verastem is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×5,000×10,000×4587OXBMGTXIVAINBXAPMDVSTMRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Verastem is the large dot.

Verastem competitors and peer comparison

How Verastem compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Verastem against its 20 peers (data as of 18 Nov 2026)
MeasureVSTMPeer medianRank in peer set
1-month return-26.4%-7.2%4th lowest of 21
6-month return+66.3%-16.4%highest of 20
Distance from 52-week high-36.5%-44.8%6th highest of 21
Revenue growth (TTM)+649.6%+2.5%2nd highest of 18
Operating margin-193.7%-25.0%5th lowest of 19
EV / Sales8.2×6.4×8th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%

Questions

Which companies are Verastem's closest peers?
The cockpit's peer set: Peptidream (4587.T), Oxford BioMedica (OXB.L), GNI (2160.T), Chengdu Kanghua Biological Products Co. Td Class 1 (300841.SZ), Odyssey Therapeutics (ODTX), Innovita Biological Technology (688253.SS), China Animal Husbandry Industry (600195.SS), MeiraGTx (MGTX).
Is Verastem expensive compared with its peers?
On ev / sales it trades at 8.2× against a peer median of 6.4×, 8th most expensive of 19 in its peer set.
How has Verastem stock performed?
Over six months to 18 Nov 2026 the shares returned +66.3% against -16.4% for the median peer; over one year -24.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.